MedTrace Logo

Olanzapine for Acute Headaches

NCT03066622 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2022-01-12

Study results available
· View outcomes & findings →

Summary

This trial is a prospective, randomized, feasibility trial with the primary aim of comparing how well oral rapidly dissolving olanzapine controls primary headache pain when compared to the current treatment strategies used in emergency departments which often require intravenous or intramuscular medications.

Conditions

Interventions

DRUG

Standard of Care as per attending physician

Patients are randomized to standard of care medication (as determined by attending physician)

DRUG

5mg rapidly dissolving olanzapine

5mg rapidly dissolving olanzapine

Sponsors & Collaborators

  • HealthPartners Institute

    lead OTHER

Principal Investigators

  • Bradley Hernandez, MD · HealthPartners Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2018-05-17
Completion
2018-05-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03066622 on ClinicalTrials.gov